



Research Repository UCD

Title	Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?
Authors(s)	Martin, William P., le Roux, Carel W.
Publication date	2020-12
Publication information	Martin, William P., and Carel W. le Roux. "Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?" Wiley, December 2020. https://doi.org/10.1002/oby.23052 .
Publisher	Wiley
Item record/more information	http://hdl.handle.net/10197/12677
Publisher's statement	This is the pre-peer reviewed version of the following article: Martin, W.P. and le Roux, C.W. (2020), Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?. Obesity, 28: 2259-2259., which has been published in final form at https://doi.org/10.1002/oby.23052 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Publisher's version (DOI)	10.1002/oby.23052

Downloaded 2025-12-04 22:29:56

The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd_oa)



© Some rights reserved. For more information

Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?

William P. Martin ¹ and Carel W. le Roux ^{1,2}


Obesity is common in people with chronic kidney disease (1) and is associated with a higher risk of kidney allograft complications (2); thus, BMI ≥ 35 kg/m² and BMI ≥ 40 kg/m² are generally considered relative and absolute contraindications, respectively, to kidney transplantation (2). Metabolic surgery improves renal outcomes in patients with type 2 diabetes (3), and diabetes is an important risk factor for renal functional decline after kidney transplantation, raising the possibility that metabolic surgery may improve graft survival and mortality in this setting (2). An understanding of the efficacy and safety of metabolic surgery in people with end-stage kidney disease (ESKD) and in kidney transplant recipients is required.

Guggino et al.'s systematic review and meta-analysis (4) of 30 studies examined the safety and efficacy of metabolic surgery in people with ESKD ($n=18$), in kidney transplant recipients ($n=14$), or in both ($n=2$). Patients with ESKD achieved expected weight loss after metabolic surgery, but postoperative mortality and complication rates were higher than in the general population at 2% and 7%, respectively. Approximately 20% of patients with ESKD subsequently received a kidney transplant after metabolic surgery. In kidney transplant recipients, metabolic surgery reduced serum creatinine and proteinuria, but Roux-en-Y gastric bypass (RYGB) increased risk of allograft rejection in one study.

The use of serum creatinine to infer changes in renal function after metabolic surgery is a limitation of the meta-analysis. This is not reliable, owing to changes in lean muscle mass postoperatively (5). Most studies were small, single center, and observational with limited follow-up. Randomized controlled trials (RCTs) of metabolic surgery in people with kidney disease are limited to early-stage chronic kidney disease (6). Abdominal surgeries are challenging in people on peritoneal dialysis; differences in outcomes of pre-transplant metabolic surgery between dialysis modalities were not explored.

RCTs investigating metabolic surgery in ESKD populations are required to understand the proportion of patients progressing to kidney transplant wait-listing, as well as duration of wait-listing and subsequent receipt of kidney transplant. Given the apparent paradox that people with obesity have better survival on maintenance dialysis, the impact of metabolic surgery on mortality in the 80% of people on dialysis who do not receive a kidney transplant postoperatively, as well as associations with sarcopenia, should be determined. Medical treatment of obesity in people with ESKD may also improve transplant candidacy. Liraglutide induced a mean weight loss of 2.4 kg after 12 weeks in people with type 2 diabetes and ESKD (7). Thus, comparator groups in RCTs of metabolic surgery in ESKD should use pharmacotherapy for obesity.

Although more data support the role of RYGB in improving metabolic, renal, and cardiovascular outcomes as well as mortality, particularly in patients with type 2 diabetes (3), sleeve gastrectomy may offer advantages in kidney transplant recipients, namely a lower risk of enteric hyperoxaluria and better immunosuppressant bioavailability (2). RCTs evaluating renal allograft outcomes after sleeve gastrectomy and RYGB should be performed in both the pre-transplant and post-transplant settings.

This study (4) provides valuable evidence that while postoperative complications and mortality after metabolic surgery increase in people with ESKD, absolute event rates remain low. The risks appear small in the context of extremely high mortality rates in ESKD. With appropriate counseling, metabolic surgery should be considered a viable treatment option for obesity among people with ESKD, and prospective studies should endeavor to establish the impact of different surgical approaches to optimize kidney transplantation rates, renal allograft outcomes, and mortality. 

Funding agencies: This work was supported by Wellcome Trust, Health Research Board, Health Service Executive National Doctors Training and Planning, and the Health and Social Care, Research and Development Division, Northern Ireland (grant number 203930/B/16/Z).

Disclosure: WPM declares no competing interests. CWIR discloses personal fees outside of the submitted work from Novo Nordisk, Gl Dynamics, Eli Lilly, Johnson and Johnson, Sanofi, Aventis, Astra Zeneca, Janssen, Bristol-Myers Squibb, and Boehringer-Ingelheim.

References

1. Martin WP, Bauer J, Coleman J, et al. Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centre. *Clin Obes* 2020:e12402. doi:10.1111/cob.12402
2. Martin WP, White J, López-Hernández FJ, Docherty NG, le Roux CW. Metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and end-stage kidney disease; what are the unanswered questions? *Front Endocrinol (Lausanne)* 2020;11:289. doi:10.3389/fendo.2020.00289
3. Martin WP, Docherty NG, Le Roux CW. Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. *Exp Rev Endocrinol Metab* 2018;13:251-262.
4. Guggino J, Coumes S, Wion N, Reche F, Arvieux C, Borel AL. Effectiveness and safety of bariatric surgery in patients with end-stage chronic kidney disease or kidney transplant. *Obesity (Silver Spring)* 2020;28:12:2290-2304.
5. Nair M, le Roux CW, Docherty NG. Measuring changes in renal function after bariatric surgery: why estimated glomerular filtration rate is not good enough. *Surg Obes Related Dis* 2016;12:1897-1898.
6. Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. *JAMA Surg* 2020;155:e200420. doi:10.1001/jamasurg.2020.0420
7. Idorn T, Knop FK, Jorgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. *Diabetes Care* 2016;39:206-213.

¹ Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland. Correspondence: Carel W. le Roux (carel.leroux@ucd.ie) ² Division of Investigative Science, Imperial College London, London, UK.

See accompanying article, pg. 2290.

© 2020 The Obesity Society. Received: 29 September 2020; Accepted: 29 September 2020; Published online 24 November 2020. doi:10.1002/oby.23052